Skip to main content
Erschienen in: Annals of Surgical Oncology 12/2010

01.12.2010 | Gastrointestinal Oncology

18F-FAMT-PET Is Useful for the Diagnosis of Lymph Node Metastasis in Operable Esophageal Squamous Cell Carcinoma

verfasst von: Makoto Sohda, Hiroyuki Kato, Shigemasa Suzuki, Naritaka Tanaka, Akihiko Sano, Makoto Sakai, Takanori Inose, Masanobu Nakajima, Tatsuya Miyazaki, Minoru Fukuchi, Noboru Oriuchi, Keigo Endo, Hiroyuki Kuwano

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

The role and potential usefulness of positron emission tomography (PET) scanning in certain tumors has been widely investigated in recent years. 18F-FAMT (L-[3-18F]-α-methyltyrosine) is an amino acid tracer for PET. This study investigated whether PET/CT with 18F-FAMT provides additional information for preoperative diagnostic workup of esophageal squamous cell carcinoma compared with that obtained by 18F-FDG (fluorodeoxyglucose) PET or CT.

Methods

PET/CT studies with 18F-FAMT and 18F-FDG were performed as a part of the preoperative workup in 21 patients with histologically confirmed esophageal squamous cell carcinoma.

Results

For the detection of primary esophageal cancer, 18F-FAMT-PET exhibited a sensitivity of 76.2%, whereas the sensitivity for 18F-FDG-PET was 90.5% (P = 0.214). 18F-FAMT uptake in primary tumors showed significant correlation with depth of invasion (P = 0.005), lymph node metastasis (P = 0.045), stage (P = 0.031), and lymphatic invasion (P = 0.029). In the evaluation of individual lymph node groups, 18F-FAMT-PET exhibited 18.2% sensitivity, 100% specificity, 71.9% accuracy, 100% positive predictive value, and 70.0% negative predictive value, compared with 24.2%, 93.7%, 69.8%, 66.6%, and 70.2%, respectively, for 18F FDG-PET. CT exhibited 39.4% sensitivity, 85.7% specificity, 69.8% accuracy, 59.1% positive predictive value, and 73.0% negative predictive value. The specificity of 18F-FAMT-PET is significantly higher than that of 18F-FDG-PET (P = 0.042) and CT (P = 0.002). 18F-FAMT-PET did not have any false-positive findings compared to those with 18F-FDG-PET.

Conclusions

Our findings suggest that the addition of 18F-FAMT-PET to 18F-FDG-PET and CT would permit more precise staging of esophageal cancer.
Literatur
1.
Zurück zum Zitat Daly JM, Karnell LH, Menck HR. National Cancer Data Base report on esophageal carcinoma. Cancer. 1996;78:1820–8.CrossRefPubMed Daly JM, Karnell LH, Menck HR. National Cancer Data Base report on esophageal carcinoma. Cancer. 1996;78:1820–8.CrossRefPubMed
2.
Zurück zum Zitat Wobst A, Audisio RA, Colleoni M, Geraghty JG. Oesophageal cancer treatment: studies, strategies and facts. Ann Oncol. 1998;9:951–62.CrossRefPubMed Wobst A, Audisio RA, Colleoni M, Geraghty JG. Oesophageal cancer treatment: studies, strategies and facts. Ann Oncol. 1998;9:951–62.CrossRefPubMed
3.
Zurück zum Zitat Kato H, Kuwano H, Nakajima M, et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer. 2002;94:921–8.CrossRefPubMed Kato H, Kuwano H, Nakajima M, et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer. 2002;94:921–8.CrossRefPubMed
4.
Zurück zum Zitat Brock CS, Meikle SR, Price P. Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology? Eur J Nucl Med. 1997;24:691–705.PubMed Brock CS, Meikle SR, Price P. Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology? Eur J Nucl Med. 1997;24:691–705.PubMed
5.
Zurück zum Zitat Kato H, Takita J, Miyazaki T, et al. Correlation of 18-F-fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma. Anticancer Res. 2003;23:3263–72.PubMed Kato H, Takita J, Miyazaki T, et al. Correlation of 18-F-fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma. Anticancer Res. 2003;23:3263–72.PubMed
6.
Zurück zum Zitat Kato H, Nakajima M, Sohda M, et al. The clinical application of 18F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer. 2009;115:3196–203.CrossRefPubMed Kato H, Nakajima M, Sohda M, et al. The clinical application of 18F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer. 2009;115:3196–203.CrossRefPubMed
7.
Zurück zum Zitat Tomiyoshi K, Amed K, Muhammad S, et al. Synthesis of isomers of 18F-labelled amino acid radiopharmaceutical: position 2- and 3-L-18F-alpha-methyltyrosine using a separation and purification system. Nucl Med Commun. 1997;18:169–75.CrossRefPubMed Tomiyoshi K, Amed K, Muhammad S, et al. Synthesis of isomers of 18F-labelled amino acid radiopharmaceutical: position 2- and 3-L-18F-alpha-methyltyrosine using a separation and purification system. Nucl Med Commun. 1997;18:169–75.CrossRefPubMed
8.
Zurück zum Zitat Inoue T, Tomiyoshi K, Higuichi T, et al. Biodistribution studies on L-3-[fluorine-18]fluoro-alpha-methyl tyrosine: a potential tumor-detecting agent. J Nucl Med. 1998;39:663–7.PubMed Inoue T, Tomiyoshi K, Higuichi T, et al. Biodistribution studies on L-3-[fluorine-18]fluoro-alpha-methyl tyrosine: a potential tumor-detecting agent. J Nucl Med. 1998;39:663–7.PubMed
9.
Zurück zum Zitat Amano S, Inoue T, Tomiyoshi K, Ando T, Endo K. In vivo comparison of PET and SPECT radiopharmaceuticals in detecting breast cancer. J Nucl Med. 1998;39:1424–7.PubMed Amano S, Inoue T, Tomiyoshi K, Ando T, Endo K. In vivo comparison of PET and SPECT radiopharmaceuticals in detecting breast cancer. J Nucl Med. 1998;39:1424–7.PubMed
10.
Zurück zum Zitat Uchino H, Kanai Y, Kim DK, et al. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol. 2002;61:729–37.CrossRefPubMed Uchino H, Kanai Y, Kim DK, et al. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol. 2002;61:729–37.CrossRefPubMed
11.
Zurück zum Zitat Kim DK, Kanai Y, Choi HW, et al. Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells. Biochim Biophys Acta. 2002;1565:112–21.CrossRefPubMed Kim DK, Kanai Y, Choi HW, et al. Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells. Biochim Biophys Acta. 2002;1565:112–21.CrossRefPubMed
12.
Zurück zum Zitat Kaira K, Oriuchi N, Otani Y, et al. Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. Chest. 2007;131:1019–27.CrossRefPubMed Kaira K, Oriuchi N, Otani Y, et al. Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. Chest. 2007;131:1019–27.CrossRefPubMed
13.
Zurück zum Zitat Kaira K, Oriuchi N, Otani Y, et al. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res. 2007;13:6369–78.CrossRefPubMed Kaira K, Oriuchi N, Otani Y, et al. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res. 2007;13:6369–78.CrossRefPubMed
14.
Zurück zum Zitat Kaira K, Oriuchi N, Shimizu K, et al. Evaluation of thoracic tumors with 18F-FMT and 18F-FDG PET-CT: a clinicopathological study. Int J Cancer. 2009;124:1152–60.CrossRefPubMed Kaira K, Oriuchi N, Shimizu K, et al. Evaluation of thoracic tumors with 18F-FMT and 18F-FDG PET-CT: a clinicopathological study. Int J Cancer. 2009;124:1152–60.CrossRefPubMed
15.
Zurück zum Zitat Japanese Society for Esophageal Disease. Guidelines for the clinical and pathological studies on carcinoma of the esophagus. 10th ed. Tokyo: Kanehara; 2008. Japanese Society for Esophageal Disease. Guidelines for the clinical and pathological studies on carcinoma of the esophagus. 10th ed. Tokyo: Kanehara; 2008.
16.
Zurück zum Zitat Hamacher K, Coenen HH, Stöcklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-d.-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235–8.PubMed Hamacher K, Coenen HH, Stöcklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-d.-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235–8.PubMed
17.
Zurück zum Zitat Beck JR. Likelihood ratios. Another enhancement of sensitivity and specificity. Arch Pathol Lab Med. 1986;110:685–6.PubMed Beck JR. Likelihood ratios. Another enhancement of sensitivity and specificity. Arch Pathol Lab Med. 1986;110:685–6.PubMed
18.
Zurück zum Zitat Kuwano H, Sumiyoshi K, Sonoda K, et al. Relationship between preoperative assessment of organ function and postoperative morbidity in patients with oesophageal cancer. Eur J Surg. 1998;164:581–6.CrossRefPubMed Kuwano H, Sumiyoshi K, Sonoda K, et al. Relationship between preoperative assessment of organ function and postoperative morbidity in patients with oesophageal cancer. Eur J Surg. 1998;164:581–6.CrossRefPubMed
19.
Zurück zum Zitat Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med. 2000;30:150–85.CrossRefPubMed Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med. 2000;30:150–85.CrossRefPubMed
20.
Zurück zum Zitat Meltzer CC, Luketich JD, Friedman D, et al. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography. Clin Nucl Med. 2000;25:882–7.CrossRefPubMed Meltzer CC, Luketich JD, Friedman D, et al. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography. Clin Nucl Med. 2000;25:882–7.CrossRefPubMed
21.
Zurück zum Zitat Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000;18:3202–10.PubMed Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000;18:3202–10.PubMed
Metadaten
Titel
18F-FAMT-PET Is Useful for the Diagnosis of Lymph Node Metastasis in Operable Esophageal Squamous Cell Carcinoma
verfasst von
Makoto Sohda
Hiroyuki Kato
Shigemasa Suzuki
Naritaka Tanaka
Akihiko Sano
Makoto Sakai
Takanori Inose
Masanobu Nakajima
Tatsuya Miyazaki
Minoru Fukuchi
Noboru Oriuchi
Keigo Endo
Hiroyuki Kuwano
Publikationsdatum
01.12.2010
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2010
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1177-y

Weitere Artikel der Ausgabe 12/2010

Annals of Surgical Oncology 12/2010 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.